Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:2:p6
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 2 (pt 6/16)
Character Range: 133947–136744

combined with one or more other therapeutically active substances in oral preparations when:
 (a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
 (b) in a day‑night pack containing doxylamine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
 except in preparations for the treatment of children under 2 years of age.
DUBOISIA LEICHHARDTII for oral use:
 (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
 (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
DUBOISIA MYOPOROIDES for oral use:
 (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
 (b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
ECONAZOLE for human use in dermal preparations except in preparations for the treatment of tinea pedis.
ESOMEPRAZOLE in oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days' supply.
ETAFEDRINE.
ETHER for therapeutic use except:
 (a) when included in Schedule 4; or
 (b) in preparations containing 10% or less of ether.
ETOFENAMATE in preparations for external use.
FAMOTIDINE when sold in the manufacturer's original pack containing not more than 14 days' supply.
FELBINAC in preparations for external use.
FEXOFENADINE in preparations for oral use except in divided preparations:
 (a) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

          (i) in a primary pack containing 20 dosage units or less and not more than 10 days' supply; and

          (ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine; or
 (b) for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

          (i) in a primary pack containing 10 dosage units or less and not more than 10 days' supply; and

          (ii) labelled with a recommended daily dose not exceeding 180 mg of fexofenadine; or
 (c) for the treatment of seasonal allergic rhinitis and children 6 years of age and